Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX) will participate in two investor conferences in November 2025.
Stifel 2025 Healthcare Conference: management will hold a fireside chat and investor meetings on Nov 11, 2025 (4:40–5:10 p.m. ET) in New York.
Jefferies 2025 Global Healthcare Conference – London: management will deliver a corporate presentation and meet investors on Nov 19, 2025 (8:00–8:25 a.m. GMT / webcast available) in London; a live webcast and replay will be available on Viking's Investors & Media Webcasts page.
Viking Therapeutics (NASDAQ: VKTX) will present clinical data and study designs for its obesity program VK2735 at ObesityWeek® 2025 (Nov 4–7, 2025) and at AHA Scientific Sessions 2025 (Nov 7–10, 2025).
ObesityWeek highlights: an exploratory analysis from the Phase 2 VENTURE study reporting 13-week effects of weekly subcutaneous VK2735 on weight, prediabetes prevalence, and metabolic syndrome, plus the Phase 3 VANQUISH-1 study design for subcutaneous VK2735 in adults with overweight or obesity.
AHA highlights: the Phase 3 VANQUISH-2 study design in Type 2 diabetes with obesity and an analysis of cardiometabolic condition prevalence across BMI categories. Presentation dates/times and presenting authors are listed for each poster.
Viking Therapeutics (NASDAQ:VKTX) reported Q3 2025 results and a corporate update on Oct 22, 2025. Key highlights include a $715 million quarter-end cash balance, Phase 3 VANQUISH program for subcutaneous VK2735 proceeding on schedule, and Phase 2 oral VENTURE topline showing up to 12.2% mean weight loss after 13 weeks. Prior subcutaneous data showed up to 14.7% mean weight loss. The company initiated a maintenance dosing study and plans an IND for an amylin agonist program in 1Q26. Q3 R&D expense rose to $90.0M from $22.8M year-ago.
Viking Therapeutics (NASDAQ: VKTX) initiated a Phase 1 randomized, double-blind, placebo-controlled maintenance dosing study of VK2735 in approximately 180 adults with obesity on Oct 21, 2025. All participants receive initial weekly subcutaneous VK2735 or placebo for 19 weeks, then transition to maintenance arms: monthly subcutaneous, weekly oral, daily oral, or placebo through Week 31.
The study will evaluate safety, tolerability, and pharmacokinetics, with exploratory endpoints including change in body weight from baseline and from Week 19 to Week 31. Viking expects to report results in 2026. Viking is also conducting two Phase 3 weekly subcutaneous trials: VANQUISH-1 (~4,500) and VANQUISH-2 (~1,100), each dosed for 78 weeks.
Viking Therapeutics (NASDAQ: VKTX) will release its third-quarter 2025 financial results after market close on Wednesday, October 22, 2025. The company will host a conference call to discuss results and corporate updates beginning at 4:30 p.m. Eastern Time the same day.
Investors may join by phone (U.S. dial-in 844-850-0543; outside U.S. 412-317-5199) or listen live via the company webcast on the Viking IR Webcasts page. A telephone replay will be available through October 29, 2025 with replay access code 8625334, and a webcast archive will be posted on the Webcasts page for 30 days.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, has announced its participation in four upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (Sept 3-5), Morgan Stanley Global Healthcare Conference (Sept 8-10), Bernstein Healthcare Forum (Sept 23-25), and Stifel Virtual Cardiometabolic Forum (Sept 30). Management will engage in fireside chats, presentations, and investor meetings.
Live webcasts will be available for the Morgan Stanley and Bernstein events through Viking's website, with replays accessible afterward in the Investors & Media section.
Viking Therapeutics (NASDAQ: VKTX) announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an oral tablet formulation targeting obesity treatment. The study achieved both primary and secondary endpoints, demonstrating significant weight loss benefits.
Key highlights include: Up to 12.2% (26.6 lbs) mean weight loss in treated patients compared to 1.3% (2.9 lbs) for placebo after 13 weeks. The trial showed impressive efficacy with up to 97% of subjects achieving ≥5% weight loss and up to 80% achieving ≥10% weight loss. The drug demonstrated a favorable safety profile with 99% of GI-related adverse events being mild or moderate.
An exploratory maintenance dosing cohort showed promising results, suggesting effective weight maintenance may be achieved at lower doses (30mg) after initial treatment with higher doses.
Viking Therapeutics (NASDAQ:VKTX) reported Q2 2025 financial results and pipeline updates. The company has initiated the Phase 3 VANQUISH registration trials for VK2735 in obesity, following successful Phase 2 results showing up to 14.7% weight reduction. The VANQUISH program includes two studies targeting approximately 5,600 patients total.
Viking completed enrollment in the Phase 2 VENTURE-Oral dosing trial for their oral obesity treatment, with results expected in 2H25. The company is also advancing its amylin agonist program with an IND planned for Q4 2025. Financial results showed a net loss of $65.6 million for Q2, with a strong cash position of $808 million as of June 30, 2025.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, will release its Q2 2025 financial results on Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide corporate updates. Investors can join via phone or watch the webcast through Viking's website. A replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days.
Viking Therapeutics (NASDAQ: VKTX) has launched its Phase 3 VANQUISH clinical program for VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The program consists of two major studies: VANQUISH-1, targeting 4,500 obese adults, and VANQUISH-2, targeting 1,100 obese/overweight adults with type 2 diabetes.
The 78-week trials will evaluate three dosing arms (7.5mg, 12.5mg, 17.5mg) against placebo, with the primary endpoint measuring body weight change. The announcement follows successful Phase 2 VENTURE study results, where VK2735 achieved up to 14.7% body weight reduction and demonstrated favorable safety profiles with mostly mild to moderate adverse events.
Viking also plans to initiate a study for monthly maintenance dosing and expects to report Phase 2 results for the oral formulation in late 2025.